Repron Therapeutics is a technology company.
Repron Therapeutics has raised $2.0M across 1 funding round.
Repron Therapeutics has raised $2.0M in total across 1 funding round.
Repron Therapeutics is an early-stage Italian biotechnology company founded in 2023 and based in Milan, developing first-in-class therapeutics targeting cancer, particularly by inhibiting oncogenes and eliminating residual tumor cells through epigenetic silencing regulators and engineered synthetic factors.[1][2][4][5] It serves oncology patients and healthcare providers by addressing complex tumor cases via innovative B2B healthcare technology that intercepts tumor malignancy based on tumor profiles.[2][4] The company has raised approximately $2.1M–$2.18M in a single funding round, showing initial growth momentum as a health tech startup in the biotech space.[2][5]
Repron Therapeutics was founded in 2023 in Milan, Italy, emerging as a health startup focused on biotechnology innovations for cancer treatment.[2][4][5] While specific founders are not detailed in available sources, the company quickly gained traction with $2.1M–$2.18M in seed funding from at least one investor, marking a pivotal early milestone in its development.[2][5] Its idea stems from advancing epigenetic technologies to target oncogenes and residual tumor cells, building on needs in tumor malignancy inhibition.[1][2][4]
Repron Therapeutics rides the wave of precision oncology and epigenetic therapies, capitalizing on trends in targeted cancer treatments amid rising demand for therapies against residual tumors and oncogene-driven malignancies.[1][2][4] Timing is favorable with global biotech investment in health tech startups, especially in Europe, where Italy's Milan ecosystem supports early-stage innovation; its $2M+ seed funding reflects market forces favoring scalable B2B solutions for complex tumors.[2][5] The company influences the ecosystem by advancing synthetic biology tools, potentially accelerating similar profiles in oncology like peers (e.g., Acesion Pharma, AbolerIS Pharma), fostering competition and collaboration in tumor-specific biotech.[2]
Repron Therapeutics is poised for milestone-driven growth, likely pursuing clinical validation of its epigenetic regulators and additional funding to scale tumor-targeting therapies.[1][4][5] Trends like AI-enhanced oncology and personalized medicine will shape its path, amplifying its edge in residual tumor elimination amid a biotech funding rebound. Its influence may evolve from niche innovator to key player in European cancer tech, building on seed momentum to impact global startup ecosystems—echoing its promise as a Milan-rooted biotech challenger in oncology.
Repron Therapeutics has raised $2.0M in total across 1 funding round.
Repron Therapeutics's investors include Claris Ventures.
Repron Therapeutics has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in June 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2023 | $2.0M Seed | Claris Ventures |